21.04.2010 • News

FDI Cooperation Gains Momentum

FDI Cooperation: f.l.t.r. Kimikazu Takahashi (Yokogawa); Jörg Freitag...
FDI Cooperation: f.l.t.r. Kimikazu Takahashi (Yokogawa); Jörg Freitag (PROFIBUS & PROFINET International); Rich Timoney (Fieldbus Foundation); Hartmut Wallraf (Invensys); Daniel Huber (ABB); Thomas Burke (OPC Foundation); Klaus-Peter Lindner (Endress+Hauser); Hans-Georg Kumpfmüller (Siemens); Martin Zielinski (Emerson); Ron Helson (HART Communication Foundation); Scott Hillmann (Honeywell); not at the picture Glenn Schulz (FDT).

Global automation suppliers ABB, Emerson Process Management, Endress+Hauser, Honeywell, Invensys, Siemens and Yokogawa have enlarged the EDDL Cooperation Team (ECT) which is now called FDI Cooperation. Along with finalizing the Field Device Integration (FDI) specification, scheduled for release in 2010, the team will also work to harmonize HART, FF and PROFIBUS device descriptions and to develop unified conformance test and integration tools.

The primary benefit of FDI is that end users with either an FDT or an EDDL-based host will have a single source solution for managing field devices. Users will no longer need to manage disparate device descriptions, which will reduce the costs associated with maintaining assets in the field.

The FDI project will also provide a very scalable solution that users can deploy in applications ranging from simple configuration to complex management of the most sophisticated field device. This makes different solutions for different devices obsolete. An example of this is that FDI device packages for applications such as valve diagnostics will provide the same functionality regardless of the host system.

Company

Siemens AG - Industry Automation and Drive Technologies

Östl. Rheinbrückenstr. 50
76187 Karlsruhe
Germany

Company contact







Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read